Impact of organic solvents on cytochrome P450 probe reactions: Filling the gap with (S)-warfarin and midazolam hydroxylation

Drug Metabolism and Disposition

Volumn 40, Issue 11, 2012, Pages 2136-2142

  González Pérez, Vanessa ^a   Connolly, Elizabeth A ^a   Bridges, Arlene S ^b   Wienkers, Larry C ^c   Paine, Mary F ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PROPANOL; ACETONE; ACETONITRILE; ALCOHOL; CYTOCHROME P450; CYTOCHROME P450 2C9; DIMETHYL SULFOXIDE; KETOCONAZOLE; METHANOL; MIDAZOLAM; WARFARIN;

ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME KINETICS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER CLEARANCE; LIVER MICROSOME; MALE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYLATION; INTESTINE, SMALL; LIVER; MICROSOMES; MICROSOMES, LIVER; MIDAZOLAM; SOLVENTS; WARFARIN;

EID: 84867671775     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.047134     Document Type: Article

References (40)

1. Abernethy DR, Kaminsky LS, and Dickinson TH (1991) Selective inhibition of warfarin metabolism by diltiazem in humans. J Pharmacol Exp Ther 257:411-415.
2. Brantley SJ, Oberlies NH, Kroll DJ, and Paine MF (2010) Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther 332:1081-1087.
3. Busby WF Jr, Ackermann JM, and Crespi CL (1999) Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27:246-249. (Pubitemid 29072079)
4. Chan E, McLachlan AJ, Pegg M, MacKay AD, Cole RB, and Rowland M (1994) Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 37:563-569. (Pubitemid 24197150)
5. Chauret N, Gauthier A, and Nicoll-Griffith DA (1998) Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1-4. (Pubitemid 28071316)
6. Draper AJ, Madan A, and Parkinson A (1997) Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 341:47-61. (Pubitemid 27198030)
7. Easterbrook J, Lu C, Sakai Y, and Li AP (2001) Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 29:141-144. (Pubitemid 32112927)
8. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, and Hall SD (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64:133-143. (Pubitemid 28423848)
9. Heimark LD, Wienkers L, Kunze K, Gibaldi M, Eddy AC, Trager WF, O'Reilly RA, and Goulart DA (1992) The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 51:398-407.
10. Hickman D, Wang JP, Wang Y, and Unadkat JD (1998) Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26:207-215. (Pubitemid 28182395)
11. Houston JB and Galetin A (2008) Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 9:940-951.
12. Houston JB, Kenworthy KE, and Galetin A (2003) Typical and atypical enzyme kinetics, in Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development (Lee JS, Obach S, Fisher MB eds) pp 211-254, Fontis Media S.A., Lausanne, Switzerland and Marcel Dekker Inc., New York.
13. Isoherranen N, Ludington SR, Givens RC, Lamba JK, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, et al. (2008) The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab Dispos 36:146-154.
14. Iwase M, Kurata N, Ehana R, Nishimura Y, Masamoto T, and Yasuhara H (2006) Evaluation of the effects of hydrophilic organic solvents on CYP3A-mediated drug-drug interaction in vitro. Hum Exp Toxicol 25:715-721. (Pubitemid 46101697)
15. Kawalek JC and Andrews AW (1980) The effect of solvents on drug metabolism in vitro. Drug Metab Dispos 8:380-384. (Pubitemid 11210385)
16. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727. (Pubitemid 29520596)
17. Kumar V, Rock DA, Warren CJ, Tracy TS, and Wahlstrom JL (2006a) Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos 34:1903-1908. (Pubitemid 44771720)
18. Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, and Tracy TS (2006b) CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34:1966-1975. (Pubitemid 44837757)
19. McAleer SD, Foondun AS, Feely M, and Chrystyn H (1997) Steady-state clearance rates of warfarin and its enantiomers in therapeutically dosed patients. Chirality 9:13-16. (Pubitemid 27149065)
20. Ngo N, Yan Z, Graf TN, Carrizosa DR, Kashuba AD, Dees EC, Oberlies NH, and Paine MF (2009) Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. Drug Metab Dispos 37:514-522.
21. Ngo N, Brantley SJ, Carrizosa DR, Kashuba AD, Dees EC, Kroll DJ, Oberlies NH, and Paine MF (2010) The warfarin-cranberry juice interaction revisited: a systematic in vitro-in vivo evaluation. J Exp Pharmacol 2010:83-91.
22. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
23. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58. (Pubitemid 27438945)
24. O'Reilly RA (1972) Sodium warfarin. Pharmacology 8:181-190.
25. Otyepka M, Berka K, and Anzenbacher P (2012) Is there a relationship between the substrate preferences and structural flexibility of cytochromes P450? Curr Drug Metab 13:130-142.
26. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
27. Rettie AE, Boberg M, Rettenmeier AW, and Baillie TA (1988) Cytochrome P-450-catalyzed desaturation of valproic acid in vitro. Species differences, induction effects, and mechanistic studies. J Biol Chem 263:13733-13738.
28. Schrag ML and Wienkers LC (2001) Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug Metab Dispos 29:70-75. (Pubitemid 32041682)
29. Seifert A, Tatzel S, Schmid RD, and Pleiss J (2006) Multiple molecular dynamics simulations of human p450 monooxygenase CYP2C9: the molecular basis of substrate binding and regioselectivity toward warfarin. Proteins 64:147-155. (Pubitemid 43830993)
30. Takahashi H, Sato T, Shimoyama Y, Shioda N, Shimizu T, Kubo S, Tamura N, Tainaka H, Yasumori T, and Echizen H (1999) Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther 66:569-581. (Pubitemid 30014082)
31. Tang C, Shou M, and Rodrigues AD (2000) Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity. Drug Metab Dispos 28:567-572. (Pubitemid 30238516)
32. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502. (Pubitemid 26193889)
33. Tsunoda SM, Velez RL, von Moltke LL, and Greenblatt DJ (1999) Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 66:461-471.
34. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, and Shader RI (1996) Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 36:783-791. (Pubitemid 26329500)
35. Wang MZ, Wu JQ, Bridges AS, Zeldin DC, Kornbluth S, Tidwell RR, Hall JE, and Paine MF (2007) Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos 35:2067-2075. (Pubitemid 350005197)
36. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833. (Pubitemid 41553963)
37. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinković D, and Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424:464-468. (Pubitemid 36917499)
38. Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, and Tucker GT (2007) Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos 35:501-502. (Pubitemid 46333921)
39. Yuan R, Madani S, Wei XX, Reynolds K, and Huang SM (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311-1319. (Pubitemid 35397032)
40. Zanger UM, Turpeinen M, Klein K, and Schwab M (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093-1108.